Gene Bio Medical (Gene Biotechnology Enterprises Ltd.)

Chair of the Board of Directors

Industry Leader in Diagnostic Technologies. Gene Bio Medical rose to the medical supply chain crisis challenges during COVID-19 pandemic, manufacturing 50 million price-competitive rapid test kits in Canada with Canadian IP approved by Health Canada Interm order II medical device class IV and FDA.  Leading the company is embarking on the project with university, municipal, provincial and federal partners to grow the Canadian bio-manufacturing industry, starting in Canada.
📍Company Overview:
Co-founded Gene Bio Medical alongside a collective of the accomplished research scientists, medical professionals, and business experts.
The company has rapidly emerged as an industry leader, specializing in immunological diagnostics, molecular diagnostics, and cutting-edge diagnostic equipment.
📍Product Portfolio:
Leads the manufacture and marketing of a diverse range of products, encompassing our proprietary technologies.
Ongoing commitment to developing innovative diagnostic solutions that advance healthcare capabilities.
Collaborates with cross-functional teams to introduce transformative technologies to the healthcare ecosystem.
📍Dedication to Health and Innovation:
Gene Bio Medical is dedicated to the research and development, as well as the manufacturing, of high-precision, cost-effective, and swift diagnostic technologies.
These technologies play a pivotal role in enhancing human health and bolstering our collective response to a wide spectrum of diseases.
📍Vision for the Future:
Committed to revolutionizing the healthcare industry through relentless innovation.
Our overarching goal is to bring about positive change for the betterment of our community by continuously pushing the boundaries of what is possible in healthcare.

Chief Executive Officer& Founder

University of Calgary

🌐NSERC-Alliance Project
Implementing Effective Crop Production and Soil Carbon Sequestration for Sustainable Agriculture | University of Calgary | 
🔬Project Overview:
Collaborated as part of the NSERC-Alliance project, led by Professor Dr. Amir Nezhad from the University of Calgary.
Focused on the development and implementation of a disruptive agricultural diagnostic technology.
The project aimed to revolutionize sustainable agriculture by monitoring greenhouse gas (GHG) emissions, soil health, and environmental risks using innovative diagnostic technology.
🔬Innovative Technology Platform:
Contributed to the development of a novel precision agriculture technology platform.
This platform had the capability to simultaneously and quantitatively monitor net GHG emissions, including CO2, N2O, and methane.
Additionally, it assessed soil health and environmental risks, providing valuable insights for various cropping and soil sequestration strategies.
🌐PRAIRIE Hub for Pandemic Preparedness
University of Calgary (Lead), University of Alberta, University of Manitoba, University of Saskatchewan | 
🔬Collaborative Pandemic Preparedness Hub:
Engaged in the PRAIRIE Hub for Pandemic Preparedness, an alliance of leading Canadian universities.
Led by the University of Calgary, this initiative brought together academic institutions with a shared mission to accelerate the development and commercialization of critical pandemic response tools.
🔬Mission and Expertise:
Focused on developing and advancing sensing reagents, biologics, in-vitro diagnostic devices, molecular diagnostic assays, sample-to-result point-of-care systems, and diagnostic equipment for potential pandemic pathogens.
Leveraged collective expertise in medical diagnostics, biomedical engineering, SME acceleration, and strategic industry partnerships.
Positioned the alliance as a prominent leader in the pandemic preparedness and response space.

Primary industry business partner

Simon Fraser University

🔬Gene Bio Medical
Commercialization Business Partner for Innovative Research Initiative | 
🧪 Collaboration Overview:
Engaged as the commercialization business partner for a groundbreaking research initiative led by renowned RNA biochemistry expert, Professor Peter Unrau, of Simon Fraser University's (SFU) Department of Molecular Biology and Biochemistry. Professor Unrau's dedicated team of nine SFU researchers is driving forward the initiative titled "Sensitive and Accurate Diagnostics for Pandemic Response and Environmental Testing."
🧪 Funding Support:
The initiative operates under the auspices of the Canada Biomedical Research Fund (CBRF) and the Biosciences Research Infrastructure Fund (BRIF), reflecting its significance in the scientific community. Aims to redefine the landscape of diagnostic technologies, bolstering global readiness for future pandemics, and expediting the translation of pivotal research findings into commercially viable products.
🧪 Commercialization Expertise:
As a pivotal partner in this ambitious endeavor, Gene Bio Medical contributes its extensive expertise and capabilities to the commercialization and manufacturing aspects of potentially groundbreaking technologies.
Our involvement ensures the seamless transition of scientific breakthroughs into practical, commercially viable solutions.
🧪 Biomedical Advancements and Global Impact:
This partnership underscores Gene Bio Medical's unwavering commitment to supporting and facilitating biomedical advancements in Canada and worldwide.
Proudly collaborating with Simon Fraser University, we play a vital role in translating significant biomedical research into practical solutions with the potential to positively impact global health.

Primary commercialization Partner

Unity Health Toronto

🔬Gene Bio Medical
Pandemic Preparedness Project (PREPARED) |
🧪Project Overview:
Spearheaded and actively contributed to the Pandemic Preparedness Project (PREPARED) at Gene Bio Medical.
Played a pivotal role in accelerating the development of diagnostics, vaccines, and treatments for pandemic preparedness.
🧪Primary Objectives:
Collaborated with primary care and emergency departments to improve healthcare delivery during pandemics.
Enhanced surveillance systems to swiftly identify and respond to infectious health threats.
Supported the seamless linkage of patients to clinical trials for cutting-edge treatments.
Leveraged collected samples to expedite the evaluation and development of vaccines, therapeutics, and diagnostics.
🧪Leadership and Vision:
Operated under the visionary leadership of Dr. Andrew D. Pinto, MD CCFP FRCPC MSc, CIHR Applied Public Health Chair in Upstream Prevention.
Contributed to the pioneering efforts of the Director of Upstream Lab at the MAP Centre for Urban Health Solutions.
🧪Coalition for Preparedness:
Part of the Canadian Hub for Health Intelligence & Innovation in Infectious Diseases, a diverse coalition of 87 academic, hospital, research networks, industry, government, not-for-profit, and community partners.
Uniting under a common mission to collectively strengthen Canada's biomanufacturing capacity, ensuring a rapid and coordinated response to future pandemics and infectious health threats.

Primary industry partner

Artron BioResearch Inc.

#Supervised Research and Development Team:
Led a diverse team of the scientists specializing in research and development within the field of human diseases. This team was tasked with exploring innovative solutions using specific Lateral flow array methods.
Oversaw the entire research process, from conceptualization to execution, ensuring the timely and successful development of new projects.
#Product Registration and Certification:
Spearheaded the registration of new products with Health Canada and other international certification bodies. This involved navigating complex regulatory landscapes, preparing documentation, and coordinating with regulatory authorities.
Successfully obtained certifications that validated the quality and safety of our products, enhancing market credibility and facilitating global distribution.
#Legal Advisory and Business Formation:
Provided strategic legal guidance to new businesses, assisting in the formation of corporations and the selection of appropriate business structures.
Drafted comprehensive privacy policies to ensure compliance with data protection regulations, safeguarding sensitive information.
Structured and negotiated commercial transactions, leveraging legal expertise to optimize business deals and protect client interests.
These achievements demonstrate my multifaceted expertise in research and development management, regulatory compliance, and legal advisory services. They underscore my ability to lead cross-functional teams, navigate regulatory complexities, and offer strategic counsel to businesses, ultimately contributing to their growth and success.

Vice President

Nankai University

#Research & Development Collaboration
Science and Technology Innovation Fund for Small and Medium-sized Technology-based Enterprises | Collaboration with Nankai University, Medical Molecular Biology Laboratory | Department of Biochemistry and Molecular Biology | Location | 2007
#Project Focus:
Collaborated with Nankai University's esteemed Medical Molecular Biology Laboratory within the Department of Biochemistry and Molecular Biology.
Actively participated in the 2007 Key Project supported by the Science and Technology Innovation Fund for Small and Medium-sized Technology-based Enterprises.
#Erythropoietin Detection Reagents (ELISA):
Led and contributed to groundbreaking research and development efforts aimed at creating advanced erythropoietin detection reagents.
Employed state-of-the-art techniques, including enzyme-linked immunosorbent assays (ELISA), to enhance the precision and sensitivity of erythropoietin measurements.
#Interdisciplinary Collaboration:
Worked at the intersection of medical molecular biology and diagnostics, fostering interdisciplinary collaboration between research teams and institutions.
Leveraged the collective expertise to drive innovation and advance the field of diagnostic reagents.
This experience underscores my commitment to scientific research, cross-institutional collaboration, and the development of cutting-edge diagnostic solutions. It reflects my ability to contribute to complex projects and leverage advanced techniques to address critical healthcare challenges.

Strategic Partnerships

Watson & Crick Biotechnology Co.,

#Production Line Development under ISO:13485 Standard:
Spearheaded the establishment of a robust production line adhering to ISO:13485 quality control standards. This involved meticulous planning, process design, and implementation to ensure compliance with stringent regulatory requirements.
Successfully integrated ISO:13485 quality management principles into our production processes, resulting in a streamlined and efficient operation that consistently met international quality benchmarks.
#Supervision of Infectious Disease Analysis Projects:
Led and managed a dedicated team of twenty scientists specializing in infectious disease analysis. The team's primary focus was on diagnosing and combating a wide range of infectious diseases.
Overseeing a portfolio of thirteen different infectious disease projects, we employed the highly sensitive and accurate ELISA technique to deliver precise and reliable results.
Fostered a collaborative and innovative work environment that encouraged knowledge-sharing and optimized project execution.
#Quality Assurance and Regulatory Compliance:
Maintained a relentless commitment to quality assurance throughout the production and analysis processes. Rigorous quality control measures were implemented at every stage to ensure the accuracy and consistency of our diagnostic reagents.
Continuously monitored and updated procedures to stay in alignment with evolving industry regulations and best practices. This proactive approach ensured ongoing regulatory compliance.
The successful establishment of an ISO:13485-compliant production line and the effective supervision of a dedicated team of scientists in analyzing thirteen types of infectious diseases using the ELISA technique are milestones that exemplify our commitment to excellence in the in vitro diagnostics industry.

VP, R&D manager

Zhongshan Bio-Tech Co.,Ltd. (中山生物工程有限公司)

Started as an intern. After graduating from University, I was promoted from being a team leader in the R&D group. My role was instrumental in driving innovation, maintaining high-quality standards, and ensuring regulatory compliance within the in vitro diagnostics industry. Made important contributions to fight against SARS during the SARS pandemic.

#Project Development Leadership:
Led a talented team of scientists in the conception, planning, and execution of innovative projects. These projects utilized advanced IVD techniques and targeted the development of diagnostic reagents for a range of diseases, including HIV1+2, HBV, TP, and EB, Complete genome sequences of four SARS viruses developed a SARS diagnostic kit . Collaborated closely with cross-functional teams to bring these projects to fruition, contributing to the accurate and timely diagnosis of life-threatening diseases.
#Quality Control and Assurance:
Established and enforced stringent quality control protocols throughout the R&D and production processes. These measures were pivotal in maintaining the highest levels of accuracy, reliability, and consistency in our diagnostic reagents. Regularly conducted thorough quality assessments, audits, and evaluations to identify opportunities for improvement and optimization.
#Regulatory Compliance:
Successfully guided the company through the complex process of achieving and maintaining industry-standard certifications. This included ISO13485, CE, FDA, and GMP certifications.
Ensured that all aspects of our operations adhered to international quality and safety standards, positioning the company as a trusted provider of in vitro diagnostic reagents.

R&D Manager

Scientist, Production and research of virus strain cultivation, monoclonal& polyclonal antibodies,Large capacity Industry partner leader. Female Entrepreneur, mentor, investor, charitarian. New venture BC judge

I’m Jessica Hu, the Female Founder of GeneBioMedical, I’m a visionary business leader committed to setting new standards in the biotechnology industry, particularly in vitro diagnostics (IVD). My ambition is driven by a desire to position GeneBio as a global leader by leveraging advanced technologies such as molecular diagnostics, immunoassays, and artificial intelligence. These innovations aim to revolutionize patient care and clinical diagnostics worldwide.
My mission is to drive innovation and achieve success by identifying and cultivating groundbreaking ideas, leading cutting-edge research initiatives, launching disruptive startups, and investing in the next big thing. I have a unique blend of scientific expertise, business acumen, and entrepreneurial vision that enables me to collaborate with various partners, such as universities, governments, and organizations, and to empower my team of talented and passionate professionals. I am also a mentor, a charitarian, where I share my insights and experience with aspiring entrepreneurs and innovators.

Taplio

Jessica H.'s Linkedin Analytics

Want to drive more opportunities from LinkedIn?

Taplio

.css-1jgreyo{background-image:linear-gradient(284deg, rgba(39,43,72,1) 0%, rgba(33,47,183,1) 100%);color:transparent;-webkit-background-clip:text;background-clip:text;}Jessica H.'s Linkedin Analytics

Want to drive more opportunities from LinkedIn?

Jessica H.'s Linkedin Analytics